💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Risedronic Acid

CHEMBL923 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
283.1 g/mol
LogP
-3.1
Phase
4

Risedronic acid (risedronate) is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone matrix and inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway of osteoclasts, impairing their function and inducing apoptosis. It is used for the prevention and treatment of osteoporosis, glucocorticoid-induced osteoporosis, Paget's disease of bone, and skeletal complications of malignancy including bone metastases.

Молекулярная масса

283,1100 g/mol

LogP

-3,10

TPSA

148,00 Ų

Правило пяти Липинского

Соответствует

Терапевтические области

Osteoporosis Epilepsy Lymphoma Breast Cancer Prostate Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
O=P(O)(O)C(O)(Cc1cccnc1)P(=O)(O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)

                

                

                

                    
                    

                        
Molecular Formula

                        
C7H11NO7P2

                    

                    
                    

                        
HBD / HBA

                        
5 / 8

                    

                    
                    

                        
Вращаемые Связи

                        
4

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
17

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
Risedronic acid (risedronate) is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone matrix and inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway of osteoclasts, impairing their function and inducing apoptosis. It is used for the prevention and treatment of osteoporosis, glucocorticoid-induced osteoporosis, Paget's disease of bone, and skeletal complications of malignancy including bone metastases.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Risedronic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL923.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5245.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.